Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan

Abstract Background Avacopan, an oral C5a receptor antagonist, demonstrated efficacy as an alternative to glucocorticoid therapy in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in the phase 3 ADVOCATE trial. However, limited real-world data exist on the outcom...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Genri Tagami, Makoto Yamaguchi, Hirokazu Sugiyama, Hiroshi Kinashi, Kentaro Imai, Keisuke Kamiya, Takayuki Katsuno, Takahiro Imaizumi, Shogo Banno, Yasuhiko Ito, Takuji Ishimoto
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-01-01
Edice:	BMC Rheumatology
Témata:	Antineutrophil cytoplasmic autoantibody-associated vasculitis Avacopan Efficacy Remission Safety
On-line přístup:	https://doi.org/10.1186/s41927-025-00456-4
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!